No Data
No Data
vcanbio cell & gene engineering corp.,ltd. (600645.SH): VUM02 injection receives drug clinical trial approval notice.
GeLongHui, September 9th | vcanbio cell & gene engineering corp.,ltd. (600645.SH) announced that its wholly-owned subsidiary wuhan guanggu vcan pharmaceutical co.,ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the approval of VUM02 injection for the treatment of systemic sclerosis on September 9. VUM02 injection (human umbilical cord mesenchymal stem cell injection) is a freeze-preserved stem cell preparation independently developed by the company, which is a new drug of human umbilical cord mesenchymal stem cells (UC-MSC) prepared from screened healthy newborn umbilical cord tissue through in vitro separation, amplification, harvesting, and cryopreservation, with clinical intentions.
Vcanbio Cell & Gene Engineering's (SHSE:600645) Soft Earnings Don't Show The Whole Picture
Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd.
vcanbio cell & gene engineering corp.,ltd. (600645.SH) released its semi-annual performance, with a net income of 85.19 million yuan, a year-on-year increase of 3.04%.
vcanbio cell & gene engineering corp.,ltd. (600645.SH) disclosed its 2024 interim report, during the reporting period, the company achieved a revenue of 8.02...
Further Weakness as Vcanbio Cell & Gene Engineering (SHSE:600645) Drops 7.1% This Week, Taking Three-year Losses to 22%
No Data
No Data